Tokushima University / Educator and Researcher Directory --- Shinomiya, Ryo

Search:

Tokushima University ⟩ Graduate School of Biomedical Sciences ⟩ 医学域 ⟩ Endwed Collaborative Research ⟩ Contribution ⟩ Department of General Medicine and Community Health Science ⟩

(Files for researchmap) [PDF manual] [Auto-propagate to researchmap]

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Koichi Okamoto, Ryo Shinomiya, Hiroyuki Ueda, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yasuyuki Okada, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto, Yasushi Sato and Tetsuji Takayama : The Future Pioneered by Intestinal Organoid Culture Technology., The Journal of Medical Investigation : JMI, 72, 3-4, 235-240, 2025. (Summary) Intestinal organoids are three-dimensional cell culture models that replicate the structure and function of the intestine, and have drawn significant attention in recent years for their potential in research and medical applications. Organoid culture technology enables the reconstruction of miniature tissues with intestinal structures, often referred to as "mini-organs", from adult stem cells or induced pluripotent stem cells. This technology allows for the faithful replication of intestinal functions and pathologies that are challenging to reproduce using conventional two-dimensional culture systems. As a result, organoid culture has emerged as a vital platform that is widely utilized in developmental biology, disease modeling, drug screening, and personalized medicine. This article focuses on the clinical applications of organoid culture technology, particularly with respect to the gastrointestinal tract, and provides an overview of its advancements and clinical potential. J. Med. Invest. 72 : 235-240, August, 2025. (Keyword) Organoids / Humans / Intestines / Cell Culture Techniques / Animals / Induced Pluripotent Stem Cells (Tokushima University Institutional Repository) ● Metadata: 2013636 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.72.235 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 41183920 ● Search Scopus @ Elsevier (PMID): 41183920 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.72.235 (Tokushima University Institutional Repository: 2013636, DOI: 10.2152/jmi.72.235, PubMed: 41183920)
2.	Yasuyuki Okada, Yasushi Sato, Ryo Shinomiya, Takanori Miyake, Taku Takahashi, Reiko Yokoyama, Yasuhiro Mitsui, Tetsu Tomonari, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Yutaka Kawano and Tetsuji Takayama : Conditions for effective use of liposomal irinotecan with fluorouracil and leucovorin in unresectable pancreatic cancer after FOLFIRINOX treatment., International Journal of Clinical Oncology, 57, 4, 1201-1210, 2025. (Summary) Liposomal irinotecan + fluorouracil/leucovorin (nal-IRI + 5FU/LV) is commonly used as a second- or later-line treatment for pancreatic ductal adenocarcinoma (PDAC) and offers survival benefits. However, its efficacy and safety in patients previously treated with FOLFIRINOX, which includes irinotecan, remain unclear. We evaluated the efficacy and safety of nal-IRI + 5FU/LV in patients with unresectable PDAC who received previous FOLFIRINOX therapy and those who did not. This retrospective observational study included 42 patients with PDAC who were treated with nal-IRI + 5FU/LV (October 2020-November 2023). Patients were grouped based on prior FOLFIRINOX treatment. The progression-free survival (PFS) in patients who previously received modified FOLFIRINOX (mFFX) therapy was shorter than that in patients who did not (2.5 vs. 3.5 months, P = 0.07). When patients with greater than- and less than the cut-off value of irinotecan-free interval (IFI) were classified into the long and short IFI groups, respectively, PFS was significantly longer in the long-IFI group than that in the short IFI group (4.0 vs. 2.1 months, P = 0.01). Moreover, the C-reactive protein/albumin ratio (CAR) was also a significant predictor of PFS (P = 0.03). Furthermore, both factors were found to be independent factors influencing PFS in the univariate Cox regression analysis (P = 0.02 and P = 0.04). Nal-IRI + 5FU/LV therapy may be a safe and effective option as a second- or later-line treatment, particularly for patients who have not previously received mFFX therapy. For patients who received prior mFFX exposure, a longer IFI and lower CAR may indicate greater potential benefit, thus aiding in more personalized treatment approaches. (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-024-02677-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 40266453 ● Search Scopus @ Elsevier (PMID): 40266453 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-024-02677-y (DOI: 10.1007/s10147-024-02677-y, PubMed: 40266453)
3.	Yasuhiro Mitsui, Yasushi Sato, Ryo Shinomiya, Satoshi Sumida, Shota Fujimoto, Akiko Okada, Takeshi Mitsuhashi, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Koichi Okamoto, Hisanori Uehara and Tetsuji Takayama : Case Report: Zolbetuximab-induced gastritis with protein-losing gastroenteropathy and hypogammaglobulinemia: a case implicating IgA vasculitis, Frontiers in Oncology, 15, 1644263, 2025. (Keyword) Claudin-18.2 / gastric cancer / gastritis / hypoalbuminemia / hypogammaglobulinemia / IgA vasculitis / protein-losing gastroenteropathy / zolbetuximab (Link to Publication Site) ● Publication site (DOI): 10.3389/fonc.2025.1644263 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-105012982726 (DOI: 10.3389/fonc.2025.1644263, Elsevier: Scopus)

Proceeding of Domestic Conference:

1.	Masahiro Sogabe, Miwako Kagawa, 米田健一, Tatsunao Sueuchi, 柴昌子, Ryo Shinomiya, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Yasuyuki Okada, 岡本耕一, 佐藤康史, Toshiya Okahisa and Tetsuji Takayama : びらん性食道炎とoral microbiotaの関連性., 第135回日本消化器内視鏡学会四国支部例会,徳島, Nov. 2025.
2.	Masahiro Sogabe, Miwako Kagawa, 米田健一, Tatsunao Sueuchi, 柴昌子, Ryo Shinomiya, 藤本将太, Takeshi Mitsuhashi, Reiko Yokoyama, 田中宏典, 三井康裕, Yutaka Kawano, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama : びらん性食道炎発症への飲酒の影響., 第135回日本消化器内視鏡学会四国支部例会,徳島, Nov. 2025.
3.	松井葉音, Toshiya Okahisa, Ryo Shinomiya, Tatsunao Sueuchi, Miwako Kagawa, 大木元彩夏, 米澤真衣, 三橋威志, 横山怜子, 川口智之, 影本開三, 喜田慶史, 三井康裕, 岡田泰行, 岡本耕一, Masahiro Sogabe, 大野将樹 and 高山哲治 : 過敏性腸症候群の診断・評価のための腸音計の開発．, 第124回日本消化器病学会四国支部例会,徳島, Nov. 2025.
4.	石川雅人, 石川寛, 佐藤純子, 続木美智, 鈴木麻由, 米田健一, Miwako Kagawa, Tatsunao Sueuchi, 柴昌子, Masahiro Sogabe, Ryo Shinomiya and Toshiya Okahisa : 大腸内視鏡検査の検査前食事制限の最適化．, 第135回日本消化器内視鏡学会四国支部例会,徳島, Nov. 2025.
5.	柴昌子, 米田健一, Tatsunao Sueuchi, Miwako Kagawa, Ryo Shinomiya, Masahiro Sogabe and Toshiya Okahisa : 腸管嚢胞状気腫症の1例．, 第135回日本消化器内視鏡学会四国支部例会,徳島, Nov. 2025.
6.	Toshiya Okahisa, 緒方良輔, Ryo Shinomiya, Tadahiko Nakagawa, Masahiro Sogabe and Tetsuji Takayama : <シンポジウム>CART専用装置(ポンプ式CART)の進歩., 第46回日本アフェレシス学会学術大会, Oct. 2025.
7.	Tadahiko Nakagawa, 岡部一郎, 緒方良輔, 小松崇俊, Ryo Shinomiya, Masahiro Sogabe, Tetsuji Takayama and Toshiya Okahisa : CART施行時の腹水処理流量の腹水中サイトカイン動態に及ぼす影響., 第46回日本アフェレシス学会学術大会, Oct. 2025.
8.	Tadahiko Nakagawa, OKABE Ichiro, 緒方良輔, 小松崇俊, Ryo Shinomiya, Masahiro Sogabe, Tetsuji Takayama and Toshiya Okahisa : CART施行時の腹水処理流量の腹水中サイトカイン動態に及ぼす影響．, 第46回日本アフェレシス学会学術大会,横浜., Oct. 2025.
9.	Toshiya Okahisa, 緒方良輔, Ryo Shinomiya, Tadahiko Nakagawa, Masahiro Sogabe and Tetsuji Takayama : <シンポジウム>CART専用装置(ポンプ式CART)の進歩．, 第46回日本アフェレシス学会学術大会,横浜, Oct. 2025.
10.	Ryo Shinomiya, Toshiya Okahisa, 米田健一, Tatsunao Sueuchi, 大木元彩夏, Reiko Yokoyama, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, 岡本耕一, Masahiro Sogabe, Masaki Oono and Tetsuji Takayama : 多数部位同時腸音解析システムを用いた腸音測定部位の最適化．, 第123回日本消化器病学会四国支部例会, 高知., Jun. 2025.
11.	中嶋健吾, Toshiya Okahisa, Ryo Shinomiya, Tatsunao Sueuchi, Miwako Kagawa, Takeshi Mitsuhashi, Hiroyuki Ueda, Masahiro Sogabe, 宮本弘志, 佐藤康史, Masaki Oono and Tetsuji Takayama : 腸音解析による腸運動の評価．, 第123回日本消化器病学会四国支部例会, 高知., Jun. 2025.
12.	大塚真人, 佐藤康史, Ryo Shinomiya, Takeshi Mitsuhashi, 吉本貴則, 川口智之, 岡本耕一, Tetsu Tomonari, 河野豊, Masahiro Sogabe, 宮本弘志 and 高山哲治 : FGFR2遺伝子異常を認めた治療抵抗性進行胃癌に対してpemigatinibが著効した一例., 第120回日本消化器病学会四国支部例会, 高知., Dec. 2023.